Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819107 | 0.85 | ADORA3 (0.53) | ADORA3ADORA2AADORA1PIK3CGALDH1A1 | |
| SCHEMBL15624141 | 0.84 | ADORA3 (0.42) | ADORA3ADORA2AADORA1GRM4PIK3CG | |
| SCHEMBL22017691 | 0.83 | GRM4 (0.44) | ADORA3ADORA2AADORA1GRM4HTT | |
| SCHEMBL22016240 | 0.82 | GRM4 (0.43) | ADORA3ADORA2AADORA1GRM4SMN1; SMN2 | |
| SCHEMBL31425940 | 0.80 | PDE3B (0.44) | ADORA3ADORA2AADORA1PIK3CGALDH1A1 | |
| SCHEMBL12251818 | 0.80 | PDE3B (0.44) | ADORA3ADORA2AADORA1PIK3CGALDH1A1 | |
| SCHEMBL280029 | 0.78 | TOP2A (0.50) | ADORA3ADORA2ASMN1; SMN2POLBCYP2D6 | |
| SCHEMBL21676746 | 0.77 | MAOA (0.39) | ADORA3ADORA2AADORA1GRM4CYP2D6 | |
| SCHEMBL13403035 | 0.76 | ADORA3 (0.44) | ADORA3ADORA2AGRM4ALDH1A1HSD17B10 | |
| SCHEMBL11624206 | 0.75 | GRM4 (0.38) | ADORA3ADORA2AADORA1GRM4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0244352-B1 | Pyrido[4,3-d]pyrimidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-31 | — | — | EP | claimed |
| JP-63045278-A | — | — | None | — | — | JP | disclosed |
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-0244352-B1 | Pyrido[4,3-d]pyrimidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
| US-4808618-A | ANTIALLERGENS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1989-02-28 | — | — | US | disclosed |
| JP-S6345278-A | NOVEL PYRIDO(4,3-D)PYRIMIDINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | NIPPON ZOKI PHARMACEUT CO LTD | 1988-02-26 | — | — | JP | disclosed |
| EP-0244352-A2 | Pyrido[4,3-d]pyrimidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | ADORA3 1301/4885ADORA2A 2840/4885ADORA1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.